Publications by authors named "Rachel Kobos"

Claim this Profile
T
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.
Luciano J Costa, Nizar J Bahlis, Aurore Perrot, Ajay K Nooka, Jin Lu, Rachel Kobos

N Engl J Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.
Aurore Perrot, Thierry Facon, Torben Plesner, Saad Z Usmani, Shaji Kumar, Rachel Kobos

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of T-cell Leukemia/Lymphoma in Children and Young Adults With the Memorial Sloan Kettering Cancer Center New York IIB Protocol.
Peter G Steinherz, Audrey Mauguen, Stephanie Suser, Kavitha Ramaswamy, Rachel Kobos

J Pediatr Hematol Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Diana Cortes-Selva, Tatiana Perova, Sheri Skerget, Deeksha Vishwamitra, Sarah Stein, Rachel Kobos

Blood· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamab.
Marie-Emilie Willemin, Shun Xin Wang Lin, Loeckie De Zwart, Liviawati S Wu, Xin Miao, Rachel Kobos

CPT Pharmacometrics Syst Pharmacol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nursing Considerations for Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma: Experience with Teclistamab from the MajesTEC-1 Study.
Donna Catamero, Patricia Blázquez Benito, Samantha Shenoy, Margaret Doyle, Jessica Fowler, Rachel Kobos

Semin Oncol Nurs· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Ajay K Nooka, Cesar Rodriguez, María Victoria Mateos, Salomon Manier, Katherine Chastain, Rachel Kobos

Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.
Thomas G Martin, Philippe Moreau, Saad Z Usmani, Alfred Garfall, María-Victoria Mateos, Rachel Kobos

Clin Lymphoma Myeloma Leuk· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
Philippe Moreau, María-Victoria Mateos, Maria Esther Gonzalez Garcia, Hermann Einsele, Valerio De Stefano, Rachel Kobos

Adv Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.
Kristine A Frerichs, Christie P M Verkleij, Maria Victoria Mateos, Thomas G Martin, Cesar Rodriguez, Rachel Kobos

Blood Adv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teclistamab: Mechanism of action, clinical, and translational science.
Yue Guo, Natalia A Quijano Cardé, Lijuan Kang, Raluca Verona, Arnob Banerjee, Rachel Kobos

Clin Transl Sci· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.
Xin Miao, Liviawati S Wu, Shun Xin Wang Lin, Yan Xu, Yang Chen, Rachel Kobos

Target Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
Thomas G Martin, Maria Victoria Mateos, Ajay Nooka, Arnob Banerjee, Rachel Kobos

Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma.
Amrita Krishnan, Ajay K Nooka, Ajai Chari, Alfred L Garfall, Thomas G Martin, Rachel Kobos

J Comp Eff Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.
Philippe Moreau, Niels W C J van de Donk, Michel Delforge, Hermann Einsele, Valerio De Stefano, Rachel Kobos

Adv Ther· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.
María-Victoria Mateos, Ajai Chari, Saad Z Usmani, Hartmut Goldschmidt, Katja Weisel, Rachel Kobos

Clin Lymphoma Myeloma Leuk· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma.
Philippe Moreau, Niels Wcj van de Donk, Hareth Nahi, Albert Oriol, Ajay K Nooka, Rachel Kobos

Future Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teclistamab in Relapsed or Refractory Multiple Myeloma.
Philippe Moreau, Alfred L Garfall, Niels W C J van de Donk, Hareth Nahi, Jesús F San-Miguel, Rachel Kobos

N Engl J Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.
Thierry Facon, Gordon Cook, Saad Z Usmani, Cyrille Hulin, Shaji Kumar, Rachel Kobos

Leukemia· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Michele Cavo, Jesus San-Miguel, Saad Z Usmani, Katja Weisel, Meletios A Dimopoulos, Rachel Kobos

Blood· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
Jesus San-Miguel, Hervé Avet-Loiseau, Bruno Paiva, Shaji Kumar, Meletios A Dimopoulos, Rachel Kobos

Blood· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
Hervé Avet-Loiseau, Jesus San-Miguel, Tineke Casneuf, Shinsuke Iida, Sagar Lonial, Rachel Kobos

J Clin Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare.
Nicole Gormley, Lola Fashoyin-Aje, Trevan Locke, Joseph M Unger, Richard F Little, Rachel Kobos

Blood Cancer Discov· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.
Aurore Perrot, Thierry Facon, Torben Plesner, Saad Z Usmani, Shaji Kumar, Rachel Kobos

J Clin Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX.
Jonathan L Kaufman, Meletios A Dimopoulos, Darrell White, Lotfi Benboubker, Gordon Cook, Rachel Kobos

Blood Cancer J· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis